Castle Biosciences (CSTL) Earnings Analysis

Castle Biosciences (CSTL) next reports earnings on 2026-07-30, consensus EPS -0.44 USD. Last quarter (2026-02-26) it beat with EPS -0.08 USD vs -0.23 USD est (+65.2%). It has beaten estimates in 6/7 recent quarters (86%). Trailing P/E -57.76.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does CSTL next report earnings?

Next earnings date2026-07-30
Consensus EPS estimate-0.44 USD
Revenue estimate0.09B

CSTL earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-02-26-0.08 USD-0.23 USD+65.2%Beat
2025-11-03-0.02 USD-0.34 USD+94.1%Beat
2025-08-040.15 USD-0.51 USD+129.4%Beat
2025-05-05-0.2 USD-0.08 USD-150%Miss
2025-02-270.32 USD-0.04 USD+900%Beat
2024-11-040.08 USD-0.06 USD+233.3%Beat
2024-08-050.31 USD-0.27 USD+214.8%Beat

Beat rate: 6/7 (86%) over reported quarters with consensus data.

CSTL valuation and analyst view

Trailing P/E-57.76
Trailing EPS-0.42932 USD
Price / book1.61
Dividend yield0.00%
Market cap0.74B
Analyst consensusBuy (11 buy / 0 hold / 0 sell)
Avg price target37.5 USD

Related research pages

Frequently asked questions

When is Castle Biosciences (CSTL)'s next earnings date?

Castle Biosciences is next scheduled to report on 2026-07-30, with a consensus EPS estimate of -0.44 USD and revenue estimate of 0.09B.

Did CSTL beat earnings last quarter?

In its 2026-02-26 report, CSTL posted EPS of -0.08 USD versus a -0.23 USD estimate — a beat of 65.2%.

What is CSTL's earnings track record?

Over the last 7 reported quarters with consensus data, CSTL beat estimates 6 times (86%).

What is CSTL's current P/E ratio and EPS?

CSTL trades at a trailing P/E of -57.76 on trailing EPS of -0.42932182408243835 USD.

What do analysts rate CSTL?

Analyst consensus is "Buy" across 11 ratings (0 strong buy, 11 buy, 0 hold, 0 sell, 0 strong sell). Average 12-month price target: 37.5 USD.